Evaluation of left ventricle function by regional fractional area change (RFAC) in a mouse model of myocardial infarction secondary to valsartan treatment

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Castiglioni, Laura ^a   Colazzo, Francesca ^b   Fontana, Lucia ^b   Colombo, Gualtiero I ^b   Piacentini, Luca ^b   Bono, Elisa ^b   Milano, Giuseppina ^b   Paleari, Serena ^a   Palermo, Annamaria ^a   Guerrini, Uliano ^a   Tremoli, Elena ^a,b   Sironi, Luigi ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPENDAGE LENGTH; ARTICLE; BODY WEIGHT; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CELL PROLIFERATION; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DUCT CONTRACTION; ECHOCARDIOGRAPHY; FIBROBLAST; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEART ATRIUM REMODELING; HEART INFARCTION; HEART LEFT ATRIUM VOLUME; HEART LEFT STROKE VOLUME; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HISTOPATHOLOGY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; QUANTITATIVE TRAIT; RADIOLOGICAL PARAMETERS; REGIONAL FRACTIONAL AREA CHANGE; SYSTOLIC BLOOD PRESSURE; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; DISEASE MODEL; DRUG EFFECTS; FEMALE; HEART VENTRICLE REMODELING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FEMALE; GENE EXPRESSION PROFILING; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIUM; VALSARTAN; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84942868633     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135778     Document Type: Article

References (42)

1. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovascular research. 2009; 81(3):482-90. Epub 2008/12/04. doi: 10.1093/cvr/cvn333 PMID: 19050008; PubMed Central PMCID: PMC2639132.
2. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000; 101(25):2981-8. Epub 2000/06/28. PMID: 10869273.
3. Lew WY, Chen ZY, Guth B, Covell JW. Mechanisms of augmented segment shortening in nonischemic areas during acute ischemia of the canine left ventricle. Circulation research. 1985; 56(3):351-8. Epub 1985/03/01. PMID: 3971509.
4. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. Journal of the American College of Cardiology. 2006; 48(10):1977-85. Epub 2006/11/23. doi: 10.1016/j.jacc.2006.07.049 PMID: 17112987.
5. Kwong RY, Sattar H, Wu H, Vorobiof G, Gandla V, Steel K, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation. 2008; 118(10):1011-20. Epub 2008/08/30. doi: 10.1161/CIRCULATIONAHA.107.727826 PMID: 18725488; PubMed Central PMCID: PMC2743310.
6. Friedrich MG. Tissue characterization of acute myocardial infarction and myocarditis by cardiac magnetic resonance. JACC Cardiovascular imaging. 2008; 1(5):652-62. Epub 2009/04/10. doi: 10.1016/j. jcmg.2008.07.011 PMID: 19356496.
7. Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. Journal of the American College of Cardiology. 2009; 54 (15):1407-24. Epub 2009/10/03. doi: 10.1016/j.jacc.2009.04.094 PMID: 19796734.
8. Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. Journal of the American College of Cardiology. 2011; 57(8):891-903. Epub 2011/02/19. doi: 10.1016/j.jacc.2010.11.013 PMID: 21329834; PubMed Central PMCID: PMC3081658.
9. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. European heart journal. 2004; 25(21):1940-65. Epub 2004/11/04. doi: 10.1016/j.ehj.2004.06.040 PMID: 15522474.
10. Mahrholdt H, Wagner A, Holly TA, Elliott MD, Bonow RO, Kim RJ, et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation. 2002; 106 (18):2322-7. Epub 2002/10/31. PMID: 12403661.
11. Kramer CM, Rogers WJ, Theobald TM, Power TP, Geskin G, Reichek N. Dissociation between changes in intramyocardial function and left ventricular volumes in the eight weeks after first anterior myocardial infarction. Journal of the American College of Cardiology. 1997; 30(7):1625-32. Epub 1997/12/31. PMID: 9385886.
12. Franzosi M, Guerrini U, Castiglioni L, Sironi L, Nobili E, Tremoli E, et al. Feasibility of quantitative analysis of regional left ventricular function in the post-infarct mouse by magnetic resonance imaging with retrospective gating. Computers in biology and medicine. 2011; 41(9):829-37. Epub 2011/07/26. doi: 10. 1016/j.compbiomed.2011.06.021 PMID: 21783184.
13. Constantine G, Shan K, Flamm SD, Sivananthan MU. Role of MRI in clinical cardiology. Lancet. 2004; 363(9427):2162-71. Epub 2004/06/29. doi: 10.1016/S0140-6736(04)16509-4 PMID: 15220041.
14. Hendel RC, Patel MR, Kramer CM, Poon M, Hendel RC, Carr JC, et al. ACCF/ACR/SCCT/SCMR/ ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. Journal of the American College of Cardiology. 2006; 48(7):1475-97. Epub 2006/10/03. doi: 10.1016/j.jacc.2006.07. 003 PMID: 17010819.
15. Okayama S, Nakano T, Uemura S, Fujimoto S, Somekawa S, Watanabe M, et al. Evaluation of left ventricular diastolic function by fractional area change using cine cardiovascular magnetic resonance: a feasibility study. Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance. 2013; 15:87. Epub 2013/09/28. doi: 10.1186/1532-429X-15-87 PMID: 24070403; PubMed Central PMCID: PMC3815234.
16. Cacciapuoti F, Scognamiglio A, Paoli VD, Romano C, Cacciapuoti F. Left Atrial Volume Index as Indicator of Left Ventricular Diastolic Dysfunction: Comparation between Left Atrial Volume Index and Tissue Myocardial Performance Index. Journal of cardiovascular ultrasound. 2012; 20(1):25-9. Epub 2012/04/18. doi: 10.4250/jcu.2012.20.1.25 PMID: 22509435; PubMed Central PMCID: PMC3324724.
17. Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, Izumo S. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiological genomics. 2004; 16(3):349-60. Epub 2003/12/18. doi: 10.1152/ physiolgenomics.00041.2003 PMID: 14679301.
18. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation. 2001; 104(22):2716-21. Epub 2001/11/28. PMID: 11723025.
19. Oishi Y, Ozono R, Yoshizumi M, Akishita M, Horiuchi M, Oshima T. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. Life sciences. 2006; 80(1):82-8. Epub 2006/10/07. doi: 10.1016/j.lfs.2006.08.033 PMID: 17023005.
20. Caiani EG, Toledo E, MacEneaney P, Bardo D, Cerutti S, Lang RM, et al. Automated interpretation of regional left ventricular wall motion from cardiac magnetic resonance images. Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance. 2006; 8 (3):427-33. Epub 2006/06/08. PMID: 16755828.
21. Colazzo F, Castiglioni L, Sironi L, Fontana L, Nobili E, Franzosi M, et al. Murine Left Atrium and Left Atrial Appendage Structure and Function: Echocardiographic and Morphologic Evaluation. PloS one. 2015; 10(4):e0125541. Epub 2015/05/01. doi: 10.1371/journal.pone.0125541 PMID: 25928887.
22. Shamir R, Maron-Katz A, Tanay A, Linhart C, Steinfeld I, Sharan R, et al. EXPANDER-an integrative program suite for microarray data analysis. BMC bioinformatics. 2005; 6:232. Epub 2005/09/24. doi: 10.1186/1471-2105-6-232 PMID: 16176576; PubMed Central PMCID: PMC1261157.
23. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic acids research. 2002; 30(1):207-10. Epub 2001/12/26. PMID: 11752295; PubMed Central PMCID: PMC99122.
24. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacological reviews. 2000; 52(1):11-34. Epub 2000/03/04. PMID: 10699153.
25. Zhao Q, Ishibashi M, Hiasa K, Tan C, Takeshita A, Egashira K. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension. 2004; 44 (3):264-70. Epub 2004/07/21. doi: 10.1161/01.HYP.0000138688.78906.6b PMID: 15262905.
26. de Gasparo M. New basic science initiatives with the angiotensin II receptor blocker valsartan. Journal of the renin-angiotensin-aldosterone system: JRAAS. 2000; 1(2 Suppl):S3-5. Epub 2007/01/03. doi: 10.3317/jraas.2000.052 PMID: 17199210.
27. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. The American journal of cardiology. 2002; 89(2A):3A-9A; discussion 10A. Epub 2002/02/12. PMID: 11835903.
28. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. Journal of the American College of Cardiology. 2002; 40(5):970-5. Epub 2002/09/13. PMID: 12225725.
29. Ramirez TA, Iyer RP, Ghasemi O, Lopez EF, Levin DB, Zhang J, et al. Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects. Journal of molecular and cellular cardiology. 2014; 72:326-35. Epub 2014/04/29. doi: 10.1016/j.yjmcc.2014.04.007 PMID: 24768766; PubMed Central PMCID: PMC4095995.
30. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circulation research. 2003; 92(8):827-39. Epub 2003/05/06. doi: 10.1161/ 01.RES.0000070112.80711.3D PMID: 12730128.
31. Schroen B, Heymans S, Sharma U, Blankesteijn WM, Pokharel S, Cleutjens JP, et al. Thrombospondin- 2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circulation research. 2004; 95(5):515-22. Epub 2004/07/31. doi: 10.1161/01.RES. 0000141019.20332.3e PMID: 15284191.
32. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Critical reviews in oncology/ hematology. 2004; 49(3):187-98. Epub 2004/03/24. doi: 10.1016/j.critrevonc.2003.09.008 PMID: 15036259.
33. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, et al. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. American journal of physiology Heart and circulatory physiology. 2005; 288(2):H461-8. Epub 2005/01/15. doi: 10.1152/ajpheart.00402.2004 PMID: 15650153.
34. Fassler R, Sasaki T, Timpl R, Chu ML, Werner S. Differential regulation of fibulin, tenascin-C, and nidogen expression during wound healing of normal and glucocorticoid-treated mice. Experimental cell research. 1996; 222(1):111-6. Epub 1996/01/10. doi: 10.1006/excr.1996.0014 PMID: 8549652.
35. Strom A, Olin AI, Aspberg A, Hultgardh-Nilsson A. Fibulin-2 is present in murine vascular lesions and is important for smooth muscle cell migration. Cardiovascular research. 2006; 69(3):755-63. Epub 2006/ 01/18. doi: 10.1016/j.cardiores.2005.12.001 PMID: 16409997.
36. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. The American journal of cardiology. 2002; 90(12):1284-9. Epub 2002/12/14. PMID: 12480035.
37. Greenberg B, Chatterjee K, Parmley WW, Werner JA, Holly AN. The influence of left ventricular filling pressure on atrial contribution to cardiac output. American heart journal. 1979; 98(6):742-51. Epub 1979/12/01. PMID: 495426.
38. Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension. 1995; 25(6):1155-60. Epub 1995/06/01. PMID: 7768556.
39. Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield MM. Diastolic dysfunction and left atrial volume: a population-based study. Journal of the American College of Cardiology. 2005; 45(1):87-92. Epub 2005/01/05. doi: 10.1016/j.jacc.2004.09.054 PMID: 15629380.
40. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999; 100(1):87-95. Epub 1999/07/07. PMID: 10393686.
41. Boixel C, Fontaine V, Rucker-Martin C, Milliez P, Louedec L, Michel JB, et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. Journal of the American College of Cardiology. 2003; 42(2):336-44. Epub 2003/07/24. PMID: 12875773.
42. Douglas PS. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. Journal of the American College of Cardiology. 2003; 42(7):1206-7. Epub 2003/10/03. PMID: 14522481.